These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 18641546

  • 1. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
    van Agteren M, Armstrong VW, van Schaik RH, de Fijter H, Hartmann A, Zeier M, Budde K, Kuypers D, Pisarski P, Le Meur Y, van der Werf M, Mamelok RD, Oellerich M, van Gelder T.
    Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
    [Abstract] [Full Text] [Related]

  • 2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 3. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 4. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
    Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y.
    Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
    [Abstract] [Full Text] [Related]

  • 5. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients.
    Heller T, van Gelder T, Budde K, de Fijter JW, Kuypers D, Arns W, Schmidt J, Rostaing L, Powis SH, Claesson K, Macphee IA, Pohanka E, Engelmayer J, Brandhorst G, Oellerich M, Armstrong VW.
    Am J Transplant; 2007 Jul; 7(7):1822-31. PubMed ID: 17532750
    [Abstract] [Full Text] [Related]

  • 6. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y, Naito T, Matsushita T, Otsuka A, Ushiyama T, Ozono S, Hishida A, Kagawa Y, Kawakami J.
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [Abstract] [Full Text] [Related]

  • 7. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.
    Yang JW, Lee PH, Hutchinson IV, Pravica V, Shah T, Min DI.
    Ther Drug Monit; 2009 Oct; 31(5):542-8. PubMed ID: 19730281
    [Abstract] [Full Text] [Related]

  • 8. Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients.
    González-Roncero FM, Govantes MA, Chaves VC, Palomo PP, Serra MB.
    Transplant Proc; 2007 Sep; 39(7):2176-8. PubMed ID: 17889129
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH.
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [Abstract] [Full Text] [Related]

  • 10. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients.
    Naito T, Mino Y, Otsuka A, Ushiyama T, Ito T, Ozono S, Kagawa Y, Kawakami J.
    J Clin Pharmacol; 2009 Jun; 49(6):710-8. PubMed ID: 19451405
    [Abstract] [Full Text] [Related]

  • 11. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
    Lévesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, Guillemette C.
    Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869
    [Abstract] [Full Text] [Related]

  • 12. Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation.
    Roan JN, Chou CH, Hsu CH, Wu SY, Huang YC, Yang YJ, Luo CY.
    Ann Transplant; 2013 Feb 05; 18():43-52. PubMed ID: 23792500
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.
    Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH.
    Ann Pharmacother; 2006 Sep 05; 40(9):1509-16. PubMed ID: 16882870
    [Abstract] [Full Text] [Related]

  • 14. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
    van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, Kuypers D, Le Meur Y, van der Werf M, Mamelok R, van Gelder T.
    Clin Pharmacol Ther; 2009 Sep 05; 86(3):319-27. PubMed ID: 19494809
    [Abstract] [Full Text] [Related]

  • 15. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.
    Patel CG, Harmon M, Gohh RY, Akhlaghi F.
    Ther Drug Monit; 2007 Feb 05; 29(1):87-95. PubMed ID: 17304155
    [Abstract] [Full Text] [Related]

  • 16. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H, Felipe CR, Slade A, Schmouder RL, Medina Pestana JO.
    Ther Drug Monit; 2012 Dec 05; 34(6):652-9. PubMed ID: 23131696
    [Abstract] [Full Text] [Related]

  • 17. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
    Merkel U, Lindner S, Vollandt R, Sperschneider H, Balogh A.
    Int J Clin Pharmacol Ther; 2005 Aug 05; 43(8):379-88. PubMed ID: 16119513
    [Abstract] [Full Text] [Related]

  • 18. Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.
    Jain AB, Hamad I, Zuckerman S, Zhang S, Warty VS, Fung JJ, Venkataramanan R.
    Liver Transpl Surg; 1999 Mar 05; 5(2):101-6. PubMed ID: 10071348
    [Abstract] [Full Text] [Related]

  • 19. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.
    Baldelli S, Merlini S, Perico N, Nicastri A, Cortinovis M, Gotti E, Remuzzi G, Cattaneo D.
    Pharmacogenomics; 2007 Sep 05; 8(9):1127-41. PubMed ID: 17924828
    [Abstract] [Full Text] [Related]

  • 20. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients.
    Djebli N, Picard N, Rérolle JP, Le Meur Y, Marquet P.
    Pharmacogenet Genomics; 2007 May 05; 17(5):321-30. PubMed ID: 17429314
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.